Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

1. A compound of Formula I:

any of its stereoisomers or any mixture of its stereoisomers,

or a pharmaceutically acceptable salt thereof;

wherein

R represents hydrogen or alkyl;

which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of:

halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and

Q represents a bicyclic aromatic group;

which bicyclic aromatic group is substituted with one or more substituents independently selected from the group consisting of:

halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, —NR′R″, —(C═O)NR′R″ or —NR′(C═O)R″;

wherein R′ and R″ independent of each other are hydrogen or alkyl.

2. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R represents hydrogen or alkyl.

3. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein

Q represents a naphthyl group or a quinolinyl group;

which group is substituted with one or more substituents independently selected from the group consisting of:

halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, —NR′R″, —(C═O)NR′R″ or —NR′(C═O)R″;

wherein R′ and R″ independent of each other are hydrogen or alkyl.

4. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein

Q represents

wherein X represents N or CH; and

R a , R b , and R d represent hydrogen and R c represents

halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, —NR′R″, —(C═O)NR′R″ or —NR′(C═O)R″;

wherein R′ and R″ independent of each other are hydrogen or alkyl.

5. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Q represents a naphthyl group,

which naphthyl group is monosubstituted with halo or alkoxy.

6. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Q represents a quinolinyl group,

which quinolinyl group is monosubstituted with nitro.

7. The chemical compound of claim 1 , which is

2-(8-Methyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-6-nitro-quinoline;

3-(6-Methoxy-naphthalen-2-yl)-8-methyl-3,8-diaza-bicyclo[3.2.1]octane;

3-(6-Bromo-naphthalen-2-yl)-8-methyl-3,8-diaza-bicyclo[3.2.1]octane;

3-(6-Ethoxy-naphthalen-2-yl)-8-methyl-3,8-diaza-bicyclo[3.2.1]octane;

2-(3,8-Diaza-bicyclo[3.2.1]oct-3-yl)-6-nitro-quinoline;

3-(6-Methoxy-naphthalen-2-yl)-3,8-diaza-bicyclo[3.2.1]octane;

3-(6-Bromo-naphthalen-2-yl)-3,8-diaza-bicyclo[3.2.1]octane;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1 , any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

9. A method of inhibiting monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1 .

10. The method according to claim 9 , wherein the disease, disorder or condition is mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, I disorder, bipolar II disorder, mood disorder due to a general medical condition, substance-induced mood disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, anxiety, generalized anxiety disorder, specific phobia, social phobia, social anxiety disorder, post-traumatic stress disorder, acute stress disorder, pain associated with depression, myofacial pain, or post-stroke depression.